The Latest Cardiac and Vascular News
THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “Common Stock”). The shares of Common Stock are being offered at a public offering price of $2.50 per […]
NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 […]
NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved LX9211 neuropathic pain Phase 2 studies expected to read out in 1H 2022 THE WOODLANDS, Texas, Jan. 13, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the […]
Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: Sotaglifozin significantly reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function studied. Sotaglifozin also significantly […]
THE WOODLANDS, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021. The new analysis will be presented by Deepak L. Bhatt, M.D., M.P.H., executive […]
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones. “We are on track for submission around year-end of our new drug application for sotagliflozin […]
New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death due to cardiovascular causes or heart failure hospitalization. THE WOODLANDS, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) — […]
Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 – The Digital Experience, including: 33% absolute risk reduction in the composite cardiovascular endpoint in type 2 diabetes patients with acute decompensated heart failure (HF), with consistent results among patients with preserved ejection fraction (HFpEF) and reduced […]
THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations […]
Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. “We remain on track to submit our New Drug Application (NDA) for sotagliflozin in heart […]
